During infancy, children received either a diphtheria, tetanus, wP, inactivated polio virus, Haemophilus influenzae type b (DTwP-IPV-Hib; Netherlands Vaccine Institute, Bilthoven, the Netherlands) (wP-primed children), or a DTaP-IPV-Hib [Infanrix-IPV-Hib™, GlaxoSmithKline (GSK), Rixensart, Belgium] (aP-primed children) combination vaccine at 2, 3, 4, and 11 months of age. Children received a pediatric DTaP booster vaccination at 4 years of age [Infanrix-IPV™, GSK; containing 25 µg pertussis toxin (PT) and filamentous hemagglutinin (FHA), 8 µg pertactin (Prn), ≥30 IU diphtheria toxoid (Dd), and ≥40 IU tetanus toxoid (Td)]. In addition, a Tdap booster vaccination was administered to children 9 years of age (Boostrix-IPV™, GSK; containing 8 µg PT and FHA, 2.5 µg Prn, ≥2 IU Dd, and ≥20 IU Td).
Infanrix ipv hib
Manufactured by GlaxoSmithKline
Sourced in Belgium
Infanrix-IPV-Hib is a combination vaccine developed by GlaxoSmithKline. It is used to prevent diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and Haemophilus influenzae type b infections in children.
Automatically generated - may contain errors
6 protocols using infanrix ipv hib
1
Childhood Vaccination Schedule Evaluation
2
Comparative Study of Childhood Vaccines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The study vaccines were DTPa-IPV/Hib vaccine (Infanrix-IPV/Hib™; GSK, Belgium), DTPa/Hib vaccine, and IPV vaccine). Each 0.5 ml dose of DTPa-IPV/Hib contained ≥30 IU DT, ≥40 IU TT, 25 μg PT, 25 μg FHA, 8 μg PRN, 40 D-antigen units poliovirus type 1, 8 D-antigen units poliovirus type 2, 32 D-antigen units poliovirus type 3, 10 μg PRP conjugated to TT, 0.5 mg aluminium as salts, and ≤2.5 mg 2-phenoxyethanol. The DTPa/Hib vaccine contained the same antigen constituents as DTPa-IPV/Hib, without the poliovirus types 1–3. The IPV vaccine contained the inactivated poliovirus types 1–3 (same amount as in the DTPa-IPV/Hib), 2-phenoxyethanol, medium 199 including amino acids, formaldehyde, polysorbate 80, water for injections, and residues of neomycin sulfate.
All vaccines were administered intramuscularly into the upper side of the right (DTPa-IPV/Hib and DTPa/Hib) or left (IPV) thigh.
All vaccines were administered intramuscularly into the upper side of the right (DTPa-IPV/Hib and DTPa/Hib) or left (IPV) thigh.
3
Infant Vaccination Schedule in the UK
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In line with UK vaccine policy, vaccinated women received tetanus, diphtheria and pertussis‐containing vaccines (Tdap); Repevax® (Sanofi Pasteur, Lyon, France; prior to July 2014) or Boostrix‐IPV® (GlaxoSmithKline, Wavre, Belgium; after July 2014). As per routine vaccination schedules in the United Kingdom, infants received three doses of tetanus, diphtheria and pertussis‐containing vaccine at 8, 12 and 16 weeks; DtaP5‐IPV‐Hib (Pediacel®; Sanofi Pasteur) or DtaP3‐IPV‐Hib (Infanrix‐IPV‐Hib®; GlaxoSmithKline). All infants received two doses of 13‐valent conjugate pneumococcal polysaccharide vaccine, Prevenar13® (Pfizer, Puurs, Belgium) at 8 and 16 weeks.
4
Childhood Vaccination Regimen and Antipyretic Use
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Participants received 3-dose primary vaccination with PHiD-CV (Synflorix™, GSK, Belgium) at 3, 4, and 5 months of age and booster dose at 12–15 months of age (intramuscular, in the right thigh, or deltoid for children >12 months); 2 doses of DTPa-HBV-IPV/Hib (Infanrix hexa™, GSK, Belgium) at 3 and 5 months of age and booster dose at 12–15 months of age (intramuscular, left thigh or deltoid); and one dose of DTPa-IPV/Hib (Infanrix-IPV/Hib™, GSK, Belgium) at 4 months of age (intramuscular, left thigh). The first dose of antipyretic (ibuprofen (Nurofen™, Reckitt Benckiser, UK) – 10 mg/kg/dose, with a maximum daily dose of 30 mg/kg, or paracetamol (Panadol Baby™, GSK, UK) – 15 mg/kg/dose with a maximum daily dose of 60 mg/kg) was administered orally either immediately after vaccination at the study site (immediate administration) or by the parents at home 4–6 hours after vaccination (delayed administration). The second and third dose of antipyretic were administered by the parents at home, 6–8 hours after the previous dose; if a child slept overnight, the dose was deferred to the following morning.
5
Vaccine Response in Immunosuppressed Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Baseline clinical assessment and chart review were performed. Varicella serology at ALL diagnosis (measured using standard clinical assays) was extracted from medical records. Vaccination records were retrieved from parents, primary care providers, public health, or medical records. Participants underwent venipuncture for immunologic markers and serology, following which they received PCV13 (Prevnar®13, Pfizer Canada Inc.) and DTaP-IPV-Hib (Pediacel®, Sanofi Pasteur Ltd or Infanrix®-IPV/Hib, GlaxoSmithKline Inc.). Two months later PPV23 (Pneumovax® 23, Merck Canada Inc. or Pneumo 23®, Sanofi Pasteur Ltd) was administered. Serum was collected approximately 2 and 12 months after the first vaccination.
6
Adverse Events in Premature Infants Immunization
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In December 2015, the Immunisation Department at PHE, through the British Association for Perinatal Medicine (BAPM), invited NNUs across England to voluntarily participate in a national audit to monitor the rate of adverse events in premature infants receiving 4CMenB concomitantly with their routine immunisations, 19 units agreed to participate. Vaccination Participating units immunised premature infants (gestational age <37 weeks at birth) as part of routine clinical care. Immunisations took place between 04/10/2015 and 25/01/2017. The administered vaccines included 4CMenB, 5-in-1 DTaP-IPV-Hib (diphtheria, tetanus, pertussis, inactivated polio and Haemophilus influenzae type b [Hib]; Infanrix-IPV-Hib®, GSK or Pediacel®, Sanofi Pasteur), the 13-valent pneumococcal conjugate vaccine (PCV13; Prevenar13®; Pfizer) and the oral rotavirus vaccine (Rotarix®; GSK Biologicals, Rixensart). Clinical Management of Infants Any blood sampling, investigations or change in clinical management was conducted at the discretion of the clinical team as part of clinical care. All samples were analysed at the infants' local hospital laboratory.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!